S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Obalon Therapeutics Stock Forecast, Price & News

-0.39 (-10.99 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $3.16
50-Day Range
MA: $4.12
52-Week Range
Now: $3.16
Volume274,793 shs
Average Volume14.18 million shs
Market Capitalization$24.56 million
P/E RatioN/A
Dividend YieldN/A
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated. The company was founded on January 2, 2008 and is headquartered in Carlsbad, CA.
Obalon Therapeutics logo


ROCE Insights For Obalon Therapeutics
January 21, 2021 |  finance.yahoo.com
Return On Capital Employed Overview: Obalon Therapeutics
December 7, 2020 |  finance.yahoo.com
Stock Alert: Obalon Therapeutics Jumps 30%
December 2, 2020 |  nasdaq.com
Obalon Therapeutics EPS misses by $0.13
November 6, 2020 |  seekingalpha.com
Obalon Announces Third Quarter 2020 Financial Results
November 6, 2020 |  finance.yahoo.com
Obalon Therapeutics Inc
October 30, 2020 |  bloomberg.com
Obalon Therapeutics, Inc. Common Stock (OBLN)
October 19, 2020 |  nasdaq.com
Obalon Therapeutics EPS misses by $0.24
July 30, 2020 |  seekingalpha.com
Obalon Announces Second Quarter 2020 Financial Results
July 30, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:OBLN
Phone(844) 362-2566
Year FoundedN/A



Sales & Book Value

Annual Sales$3.28 million
Book Value$2.06 per share


Net Income$-23,680,000.00
Net Margins-688.07%


Market Cap$24.56 million
Next Earnings Date3/4/2021 (Estimated)


Overall MarketRank

0.48 out of 5 stars

Medical Sector

1574th out of 1,968 stocks

Surgical & Medical Instruments Industry

144th out of 169 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.39 (-10.99 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

Is Obalon Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Obalon Therapeutics stock.
View analyst ratings for Obalon Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Obalon Therapeutics?

Wall Street analysts have given Obalon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Obalon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Obalon Therapeutics?

Obalon Therapeutics saw a drop in short interest in February. As of February 12th, there was short interest totaling 443,000 shares, a drop of 44.8% from the January 28th total of 802,500 shares. Based on an average daily volume of 12,960,000 shares, the days-to-cover ratio is currently 0.0 days.
View Obalon Therapeutics' Short Interest

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Obalon Therapeutics

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics, Inc. (NASDAQ:OBLN) posted its quarterly earnings results on Friday, November, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.13. The business had revenue of $0.04 million for the quarter. Obalon Therapeutics had a negative trailing twelve-month return on equity of 159.14% and a negative net margin of 688.07%.
View Obalon Therapeutics' earnings history

How has Obalon Therapeutics' stock price been impacted by COVID-19?

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OBLN stock has increased by 203.8% and is now trading at $3.16.
View which stocks have been most impacted by COVID-19

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics's stock reverse split on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the following people:
  • Andrew P. Rasdal, President, Chief Executive Officer & Director
  • Nooshin Hussainy, Chief Financial Officer
  • Mark Brister, Chief Technology Officer
  • Amy VandenBerg, Chief Clinical & Regulatory Affairs Officer
  • Daina Schmidt, Vice President-Marketing

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX), Co-Diagnostics (CODX), NIO (NIO), Novavax (NVAX) and Onconova Therapeutics (ONTX).

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (14.16%), HighPoint Advisor Group LLC (0.56%) and Virtu Financial LLC (0.35%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy and William J Plovanic.
View institutional ownership trends for Obalon Therapeutics

Which major investors are buying Obalon Therapeutics stock?

OBLN stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, HighPoint Advisor Group LLC, and Virtu Financial LLC. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Nooshin Hussainy, and William J Plovanic.
View insider buying and selling activity for Obalon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $3.16.

How much money does Obalon Therapeutics make?

Obalon Therapeutics has a market capitalization of $24.56 million and generates $3.28 million in revenue each year.

How many employees does Obalon Therapeutics have?

Obalon Therapeutics employs 2 workers across the globe.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is www.obalon.com.

Where are Obalon Therapeutics' headquarters?

Obalon Therapeutics is headquartered at 5421 Avenida Encinas Suite F, Carlsbad CA, 92008.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at (844) 362-2566 or via email at [email protected]

This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.